SEATTLE–(BUSINESS WIRE)–LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the U.S. Food & Drug Administration (FDA) has authorized marketing of Valeda® Light Delivery System for treatment of patients with dry age-related macular degeneration (AMD), a leading cause of central vision loss in people over 55 in … Continue reading LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision